GRITSTONE BIO, INC.

(GRTS)
  Report
Real-time Estimate Cboe BZX  -  03:23 2022-08-17 pm EDT
4.455 USD   -6.21%
07:01aGritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
08/15Nature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors
AQ
08/15Gritstone bio, Inc. Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 321171874347--
Enterprise Value (EV)1 193-0,43673324351166
P/E ratio -3,19x-1,41x-13,5x-3,07x-2,98x-3,39x
Yield ------
Capitalization / Revenue 73,6x42,3x18,1x18,0x24,6x54,9x
EV / Revenue 44,3x-0,11x14,0x16,9x24,9x26,3x
EV / EBITDA -2,08x0,00x-9,77x-2,69x-2,45x-0,98x
Price to Book 2,43x-----
Nbr of stocks (in thousands) 35 80643 30767 98873 007--
Reference price (USD) 8,973,9412,94,754,754,75
Announcement Date 03/11/202003/11/202103/10/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 4,374,0448,219,214,16,31
EBITDA1 -93,2-99,4-68,9-120-143-169
Operating profit (EBIT)1 -97,9-106-75,2-124-142-157
Operating Margin -2 244%-2 626%-156%-648%-1 010%-2 487%
Pre-Tax Profit (EBT)1 -94,4-105-75,1-123-139-147
Net income1 -94,4-105-75,1-123-139-147
Net margin -2 163%-2 609%-156%-642%-984%-2 332%
EPS2 -2,81-2,79-0,95-1,55-1,59-1,40
Dividend per Share ------
Announcement Date 03/11/202003/11/202103/10/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1
Net sales1 3,067,195,473,263,283,83
EBITDA ------
Operating profit (EBIT)1 -29,8-29,0-29,7-32,7-33,1-36,8
Operating Margin -972%-403%-542%-1 003%-1 010%-960%
Pre-Tax Profit (EBT)1 -29,8-28,9-29,5-32,2-32,6-
Net income1 -29,8-28,9-29,5-32,2-32,6-
Net margin -972%-402%-539%-989%-995%-
EPS2 -0,36-0,34-0,34-0,42-0,42-0,48
Dividend per Share ------
Announcement Date 03/10/202205/05/202208/04/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 ----4,59-
Net Cash position1 12817120223,0-181
Leverage (Debt / EBITDA) 1,37x1,72x2,93x0,19x-0,03x1,07x
Free Cash Flow1 -101-92,6-123-133-161-188
ROE (Net Profit / Equities) ------
Shareholders' equity1 ------
ROA (Net Profit / Asset) ------
Assets1 ------
Book Value Per Share 3,70-----
Cash Flow per Share -2,53-----
Capex 16,2-----
Capex / Sales 371%-----
Announcement Date 03/11/202003/11/202103/10/2022---
1 USD in Million
Previous periodNext period
Estimates
Key data
Capitalization (USD) 346 782 879
Net sales (USD) 48 214 000
Number of employees 193
Sales / Employee (USD) 249 813
Free-Float 97,0%
Free-Float capitalization (USD) 336 497 880
Avg. Exchange 20 sessions (USD) 4 895 954
Average Daily Capital Traded 1,41%
EPS & Dividend